The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...

WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...

Pharmacy benefit managers "are raking in billions in excess revenue—$7.3 billion over just five years—while squeezing ...

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...

Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.

The report is the latest indictment of America’s broken healthcare system.

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The report found top pharmacy benefit managers made more than $7.3 billion by marking up the prices of dozens of generic ...